SE504336C2 - Indolderivat - Google Patents

Indolderivat

Info

Publication number: SE504336C2
Authority: SE; Sweden
Prior art keywords: compound; group; compound according; metabolically labile; formula
Prior art date: 1992-04-16

Application number

SE9301241A

Other languages

English (en)

Swedish (sv)

Other versions

SE9301241D0 (sv

SE9301241L (sv

Inventor

Alfredo Cugola

Giovanni Gaviraghi

Original Assignee

Glaxo Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-04-16

Filing date

1993-04-15

Publication date

1997-01-13

1993-04-15 Application filed by Glaxo Spa filed Critical Glaxo Spa

1993-04-15 Publication of SE9301241D0 publication Critical patent/SE9301241D0/xx

1993-10-17 Publication of SE9301241L publication Critical patent/SE9301241L/xx

1997-01-13 Publication of SE504336C2 publication Critical patent/SE504336C2/sv

Links

150000002475 indoles Chemical class 0.000 title description 2
229940054051 antipsychotic indole derivative Drugs 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 64
150000003839 salts Chemical class 0.000 claims abstract description 18
150000002148 esters Chemical class 0.000 claims abstract description 17
238000000034 method Methods 0.000 claims abstract description 12
239000003257 excitatory amino acid Substances 0.000 claims abstract description 7
230000002461 excitatory amino acid Effects 0.000 claims abstract description 7
238000002360 preparation method Methods 0.000 claims abstract description 5
239000003814 drug Substances 0.000 claims abstract description 4
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims abstract description 3
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 8
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims description 7
108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims description 7
125000006239 protecting group Chemical group 0.000 claims description 7
230000000694 effects Effects 0.000 claims description 6
230000003042 antagnostic effect Effects 0.000 claims description 5
125000004494 ethyl ester group Chemical group 0.000 claims description 4
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 3
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
238000002560 therapeutic procedure Methods 0.000 claims description 3
239000000969 carrier Substances 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
159000000000 sodium salts Chemical class 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 claims 1
-1 hydroxy, methoxy Chemical group 0.000 abstract description 24
125000000217 alkyl group Chemical group 0.000 abstract description 4
239000005557 antagonist Substances 0.000 abstract description 4
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
101100496169 Arabidopsis thaliana CLH1 gene Proteins 0.000 abstract 1
101100044057 Mesocricetus auratus SYCP3 gene Proteins 0.000 abstract 1
101100080600 Schizosaccharomyces pombe (strain 972 / ATCC 24843) nse6 gene Proteins 0.000 abstract 1
125000003545 alkoxy group Chemical group 0.000 abstract 1
125000003282 alkyl amino group Chemical group 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
101150111293 cor-1 gene Proteins 0.000 abstract 1
125000004093 cyano group Chemical group *C#N 0.000 abstract 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
125000004663 dialkyl amino group Chemical group 0.000 abstract 1
125000002534 ethynyl group Chemical group [H]C#C* 0.000 abstract 1
229910052736 halogen Inorganic materials 0.000 abstract 1
150000002367 halogens Chemical class 0.000 abstract 1
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
125000004430 oxygen atom Chemical group O* 0.000 abstract 1
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
239000000203 mixture Substances 0.000 description 28
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 16
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
239000007787 solid Substances 0.000 description 14
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
239000004480 active ingredient Substances 0.000 description 11
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 10
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 10
238000005160 1H NMR spectroscopy Methods 0.000 description 9
239000000243 solution Substances 0.000 description 9
239000003826 tablet Substances 0.000 description 9
238000003756 stirring Methods 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
239000000843 powder Substances 0.000 description 7
239000002904 solvent Substances 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
239000008101 lactose Substances 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 6
238000011282 treatment Methods 0.000 description 6
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
239000004471 Glycine Substances 0.000 description 5
241000699670 Mus sp. Species 0.000 description 5
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 5
QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 5
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
241001279009 Strychnos toxifera Species 0.000 description 5
239000002775 capsule Substances 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
230000032050 esterification Effects 0.000 description 5
238000005886 esterification reaction Methods 0.000 description 5
235000019441 ethanol Nutrition 0.000 description 5
238000009472 formulation Methods 0.000 description 5
229960005453 strychnine Drugs 0.000 description 5
239000000725 suspension Substances 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
229920000168 Microcrystalline cellulose Polymers 0.000 description 4
HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 description 4
238000007796 conventional method Methods 0.000 description 4
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
235000019813 microcrystalline cellulose Nutrition 0.000 description 4
229940016286 microcrystalline cellulose Drugs 0.000 description 4
239000008108 microcrystalline cellulose Substances 0.000 description 4
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
239000002244 precipitate Substances 0.000 description 4
239000000600 sorbitol Substances 0.000 description 4
235000010356 sorbitol Nutrition 0.000 description 4
206010010904 Convulsion Diseases 0.000 description 3
229920002785 Croscarmellose sodium Polymers 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
125000005041 acyloxyalkyl group Chemical group 0.000 description 3
125000005907 alkyl ester group Chemical group 0.000 description 3
125000004103 aminoalkyl group Chemical group 0.000 description 3
238000000576 coating method Methods 0.000 description 3
229960001681 croscarmellose sodium Drugs 0.000 description 3
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 3
230000006378 damage Effects 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
DGXMYSHVJMOWMA-CMDGGOBGSA-N ethyl 3-[(e)-3-anilino-3-oxoprop-1-enyl]-4,6-dichloro-1h-indole-2-carboxylate Chemical compound CCOC(=O)C=1NC2=CC(Cl)=CC(Cl)=C2C=1\C=C\C(=O)NC1=CC=CC=C1 DGXMYSHVJMOWMA-CMDGGOBGSA-N 0.000 description 3
238000001914 filtration Methods 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
229940014259 gelatin Drugs 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
239000008107 starch Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
229940032147 starch Drugs 0.000 description 3
UUDAMDVQRQNNHZ-UHFFFAOYSA-N (S)-AMPA Chemical compound CC=1ONC(=O)C=1CC(N)C(O)=O UUDAMDVQRQNNHZ-UHFFFAOYSA-N 0.000 description 2
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
WZBNEZWCNKUOSM-UHFFFAOYSA-N 3-(3-anilino-3-oxoprop-1-enyl)-4,6-dichloro-1H-indole-2-carboxylic acid Chemical compound OC(=O)C=1NC2=CC(Cl)=CC(Cl)=C2C=1C=CC(=O)NC1=CC=CC=C1 WZBNEZWCNKUOSM-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
206010021143 Hypoxia Diseases 0.000 description 2
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
208000006011 Stroke Diseases 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
239000002585 base Substances 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
125000002843 carboxylic acid group Chemical group 0.000 description 2
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
230000036461 convulsion Effects 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 2
WZBNEZWCNKUOSM-VOTSOKGWSA-N gavestinel Chemical compound OC(=O)C=1NC2=CC(Cl)=CC(Cl)=C2C=1\C=C\C(=O)NC1=CC=CC=C1 WZBNEZWCNKUOSM-VOTSOKGWSA-N 0.000 description 2
239000011521 glass Substances 0.000 description 2
208000014674 injury Diseases 0.000 description 2
208000028867 ischemia Diseases 0.000 description 2
239000007788 liquid Substances 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
JIKUXBYRTXDNIY-UHFFFAOYSA-N n-methyl-n-phenylformamide Chemical compound O=CN(C)C1=CC=CC=C1 JIKUXBYRTXDNIY-UHFFFAOYSA-N 0.000 description 2
230000004770 neurodegeneration Effects 0.000 description 2
208000015122 neurodegenerative disease Diseases 0.000 description 2
231100000189 neurotoxic Toxicity 0.000 description 2
230000002887 neurotoxic effect Effects 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
239000012044 organic layer Substances 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
239000011591 potassium Substances 0.000 description 2
229940069328 povidone Drugs 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
238000003825 pressing Methods 0.000 description 2
239000000651 prodrug Substances 0.000 description 2
229940002612 prodrug Drugs 0.000 description 2
239000000047 product Substances 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
239000012453 solvate Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
238000012360 testing method Methods 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
238000012546 transfer Methods 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
LORJLEXVRAHTFL-UHFFFAOYSA-N (2-anilino-2-oxoethyl)-triphenylphosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1NC(=O)C[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 LORJLEXVRAHTFL-UHFFFAOYSA-N 0.000 description 1
LDDMACCNBZAMSG-BDVNFPICSA-N (2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-2-(methylamino)hexanal Chemical compound CN[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO LDDMACCNBZAMSG-BDVNFPICSA-N 0.000 description 1
BDXZOJVMTJOAPS-UHFFFAOYSA-N (3,5-dichlorophenyl)hydrazine;hydron;chloride Chemical compound Cl.NNC1=CC(Cl)=CC(Cl)=C1 BDXZOJVMTJOAPS-UHFFFAOYSA-N 0.000 description 1
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
ONZWFHWHTYZZLM-UHFFFAOYSA-N 1-chloroethyl cyclohexyl carbonate Chemical compound CC(Cl)OC(=O)OC1CCCCC1 ONZWFHWHTYZZLM-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical group C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 1
KKFDCBRMNNSAAW-UHFFFAOYSA-N 2-(morpholin-4-yl)ethanol Chemical compound OCCN1CCOCC1 KKFDCBRMNNSAAW-UHFFFAOYSA-N 0.000 description 1
125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
CPDWQQAYWLECJN-ZHACJKMWSA-N 3-[(E)-3-anilino-3-oxoprop-1-enyl]-4,6-dichloro-2-[2-(diethylamino)ethyl]indole-2-carboxylic acid Chemical compound CCN(CC)CCC1(C(=C2C(=CC(=CC2=N1)Cl)Cl)/C=C/C(=O)NC3=CC=CC=C3)C(=O)O CPDWQQAYWLECJN-ZHACJKMWSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
206010002660 Anoxia Diseases 0.000 description 1
241000976983 Anoxia Species 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
208000031104 Arterial Occlusive disease Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
201000006474 Brain Ischemia Diseases 0.000 description 1
208000014644 Brain disease Diseases 0.000 description 1
QEEMFNCVGFLSRZ-OUKQBFOZSA-N C1(CCCCC1)OC(=O)OC(C)OC(=O)C=1NC2=CC(=CC(=C2C=1\C=C\C(=O)NC1=CC=CC=C1)Cl)Cl Chemical compound C1(CCCCC1)OC(=O)OC(C)OC(=O)C=1NC2=CC(=CC(=C2C=1\C=C\C(=O)NC1=CC=CC=C1)Cl)Cl QEEMFNCVGFLSRZ-OUKQBFOZSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
206010008120 Cerebral ischaemia Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
244000060011 Cocos nucifera Species 0.000 description 1
235000013162 Cocos nucifera Nutrition 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
201000010374 Down Syndrome Diseases 0.000 description 1
208000032274 Encephalopathy Diseases 0.000 description 1
XXRCUYVCPSWGCC-UHFFFAOYSA-N Ethyl pyruvate Chemical compound CCOC(=O)C(C)=O XXRCUYVCPSWGCC-UHFFFAOYSA-N 0.000 description 1
238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
208000013016 Hypoglycemia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061216 Infarction Diseases 0.000 description 1
VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229920000715 Mucilage Polymers 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
206010028923 Neonatal asphyxia Diseases 0.000 description 1
208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 description 1
208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 1
206010029279 Neurogenic bladder Diseases 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
241000700159 Rattus Species 0.000 description 1
206010039966 Senile dementia Diseases 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
239000004141 Sodium laurylsulphate Substances 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000003513 alkali Substances 0.000 description 1
229910001854 alkali hydroxide Inorganic materials 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000008044 alkali metal hydroxides Chemical class 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
VLSMHEGGTFMBBZ-UHFFFAOYSA-N alpha-Kainic acid Natural products CC(=C)C1CNC(C(O)=O)C1CC(O)=O VLSMHEGGTFMBBZ-UHFFFAOYSA-N 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000007953 anoxia Effects 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
239000000010 aprotic solvent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
208000021328 arterial occlusion Diseases 0.000 description 1
125000005002 aryl methyl group Chemical group 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229940049706 benzodiazepine Drugs 0.000 description 1
150000001557 benzodiazepines Chemical class 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
208000029162 bladder disease Diseases 0.000 description 1
238000007664 blowing Methods 0.000 description 1
239000012267 brine Substances 0.000 description 1
235000014121 butter Nutrition 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
229960004424 carbon dioxide Drugs 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
206010008118 cerebral infarction Diseases 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
GGRHYQCXXYLUTL-UHFFFAOYSA-N chloromethyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OCCl GGRHYQCXXYLUTL-UHFFFAOYSA-N 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
229960003920 cocaine Drugs 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000002920 convulsive effect Effects 0.000 description 1
239000012043 crude product Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
229940042935 dichlorodifluoromethane Drugs 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
206010013663 drug dependence Diseases 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
YLAHLUPONQVSOT-UHFFFAOYSA-N ethyl 4,6-dichloro-1h-indole-2-carboxylate Chemical compound C1=C(Cl)C=C2NC(C(=O)OCC)=CC2=C1Cl YLAHLUPONQVSOT-UHFFFAOYSA-N 0.000 description 1
NFILHPVBZNKVNP-UHFFFAOYSA-N ethyl 4,6-dichloro-3-formyl-1h-indole-2-carboxylate Chemical compound ClC1=CC(Cl)=C2C(C=O)=C(C(=O)OCC)NC2=C1 NFILHPVBZNKVNP-UHFFFAOYSA-N 0.000 description 1
229960003750 ethyl chloride Drugs 0.000 description 1
229940117360 ethyl pyruvate Drugs 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000010419 fine particle Substances 0.000 description 1
238000003818 flash chromatography Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
208000015362 glutaric aciduria Diseases 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000007574 infarction Effects 0.000 description 1
238000002329 infrared spectrum Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 description 1
239000013067 intermediate product Substances 0.000 description 1
208000020658 intracerebral hemorrhage Diseases 0.000 description 1
238000000185 intracerebroventricular administration Methods 0.000 description 1
208000001286 intracranial vasospasm Diseases 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
230000001057 ionotropic effect Effects 0.000 description 1
230000000622 irritating effect Effects 0.000 description 1
VLSMHEGGTFMBBZ-OOZYFLPDSA-N kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 1
229950006874 kainic acid Drugs 0.000 description 1
201000010901 lateral sclerosis Diseases 0.000 description 1
239000010410 layer Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
QABLOFMHHSOFRJ-UHFFFAOYSA-N methyl 2-chloroacetate Chemical compound COC(=O)CCl QABLOFMHHSOFRJ-UHFFFAOYSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
208000005264 motor neuron disease Diseases 0.000 description 1
GTWJETSWSUWSEJ-UHFFFAOYSA-N n-benzylaniline Chemical compound C=1C=CC=CC=1CNC1=CC=CC=C1 GTWJETSWSUWSEJ-UHFFFAOYSA-N 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
230000000626 neurodegenerative effect Effects 0.000 description 1
230000000324 neuroprotective effect Effects 0.000 description 1
229960002715 nicotine Drugs 0.000 description 1
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
125000006502 nitrobenzyl group Chemical group 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
229940127240 opiate Drugs 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
230000036407 pain Effects 0.000 description 1
208000033300 perinatal asphyxia Diseases 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000137 polyphosphoric acid Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
239000003380 propellant Substances 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
238000010992 reflux Methods 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
235000020374 simple syrup Nutrition 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
229960002920 sorbitol Drugs 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
208000020431 spinal cord injury Diseases 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
208000005809 status epilepticus Diseases 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000002511 suppository base Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000000454 talc Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
238000010998 test method Methods 0.000 description 1
CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Addiction (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)

SE9301241A 1992-04-16 1993-04-15 Indolderivat SE504336C2 (sv)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB929208492A GB9208492D0 (en)	1992-04-16	1992-04-16	Heterocyclic compounds

Publications (3)

Publication Number	Publication Date
SE9301241D0 SE9301241D0 (sv)	1993-04-15
SE9301241L SE9301241L (sv)	1993-10-17
SE504336C2 true SE504336C2 (sv)	1997-01-13

Family

ID=10714220

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE9301241A SE504336C2 (sv)	1992-04-16	1993-04-15	Indolderivat

Country Status (41)

Country	Link
US (4)	US5374648A (fr)
EP (1)	EP0568136A1 (fr)
JP (2)	JPH0649027A (fr)
KR (1)	KR100264114B1 (fr)
CN (1)	CN1042331C (fr)
AP (1)	AP480A (fr)
AT (1)	AT403917B (fr)
AU (1)	AU666927B2 (fr)
BE (1)	BE1006343A5 (fr)
BG (1)	BG62136B1 (fr)
BR (1)	BR1100323A (fr)
CA (3)	CA2094073A1 (fr)
CH (1)	CH685630A5 (fr)
CY (1)	CY2038B1 (fr)
CZ (1)	CZ285799B6 (fr)
DK (1)	DK169890B1 (fr)
ES (1)	ES2105924B1 (fr)
FI (1)	FI106198B (fr)
FR (1)	FR2690919B1 (fr)
GB (2)	GB9208492D0 (fr)
GE (1)	GEP19991704B (fr)
GR (1)	GR1001619B (fr)
HK (1)	HK95797A (fr)
HU (2)	HU217964B (fr)
IL (1)	IL105412A (fr)
IS (1)	IS3994A (fr)
IT (1)	IT1265325B1 (fr)
LU (1)	LU88248A1 (fr)
MX (1)	MX9302195A (fr)
MY (1)	MY112232A (fr)
NO (1)	NO301879B1 (fr)
NZ (1)	NZ247413A (fr)
OA (1)	OA10103A (fr)
PL (1)	PL176451B1 (fr)
RO (1)	RO113242B1 (fr)
RU (1)	RU2129544C1 (fr)
SE (1)	SE504336C2 (fr)
SK (1)	SK281941B6 (fr)
TW (1)	TW224457B (fr)
WO (1)	WO1993021153A1 (fr)
ZA (1)	ZA932642B (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9304500D0 (en) *	1993-03-05	1993-04-21	Glaxo Spa	Heterocyclic compounds
US5519048A (en) *	1993-05-27	1996-05-21	Merrell Pharmaceuticals Inc.	3-(indol-3-yl)-propenoic acid derivatives and pharmaceutical compositions thereof
CN1051302C (zh) *	1993-05-27	2000-04-12	默里尔药物公司	3－(吲哚－3－基)丙烯酸衍生物及其用作nmda拮抗剂
GB9319243D0 (en) *	1993-09-17	1993-11-03	Glaxo Spa	Heterocyclic compounds
GB9321221D0 (en) *	1993-10-14	1993-12-01	Glaxo Spa	Heterocyclic compounds
TW280819B (fr) *	1993-11-17	1996-07-11	Sumitomo Pharma
US5563157B1 (en) *	1994-10-31	1999-02-02	Hoecst Marion Roussel Inc	Heterocycle substituted propenoic acid derivatives and pharmaceutical compositions thereof
GB9502695D0 (en) *	1995-02-11	1995-03-29	Glaxo Spa	Pharmaceutical composition
GB9504361D0 (en) *	1995-03-04	1995-04-26	Glaxo Spa	Heterocyclic compounds
AU4416197A (en) *	1996-09-17	1998-04-14	Regents Of The University Of California, The	Positive ampa receptor modulation to enhance brain neurotrophic factor expression
IL129187A0 (en) *	1996-09-30	2000-02-17	Hoechst Marion Roussel Inc	NMDA (N-methyl-D-aspartate) antagonists
US5922752A (en) *	1997-06-11	1999-07-13	Hoechst Marion Roussell, Inc.	NMDA (n-methyl-d-aspartate) antagonists
PT2198858E (pt) *	1998-03-26	2011-09-01	Astellas Pharma Inc	Composição farmacêutica de libertação constante que contém um macrólido como o tacrolimus
HK1054231A1 (en) *	2000-07-31	2003-11-21	Dainippon Sumitomo Pharma Co., Ltd.	Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient
WO2003039540A2 (fr) *	2001-11-09	2003-05-15	Sepracor Inc.	Inhibiteurs de d-amino acide oxydase destines a l'apprentissage et a la memoire
CA2468544A1 (fr) *	2001-12-10	2003-06-19	Amgen Inc.	Ligands de recepteur vanilloide et utilisation de ceux-ci dans des traitements
PA8579701A1 (es) *	2002-08-23	2005-05-24	Pfizer Prod Inc	Profarmaco inhibidor de beta-lactamasa
DE10306202A1 (de) *	2003-02-13	2004-08-26	Grünenthal GmbH	Arzneimittel enthaltend substituierte 2-Aryl-Aminoessigsäure-Verbindungen und/oder substituierte 2-Heteroaryl-Aminoessigsäure-Verbindungen
EP1636240A1 (fr) *	2003-06-05	2006-03-22	Pfizer Products Inc.	Promedicament inhibiteur de la beta-lactamase
RU2247563C1 (ru) *	2003-06-16	2005-03-10	Пятигорская государственная фармацевтическая академия	Способ получения твердой лекарственной формы, содержащей глюкозамина гидрохлорид
US7671072B2 (en) *	2003-11-26	2010-03-02	Pfizer Inc.	Aminopyrazole derivatives as GSK-3 inhibitors
CN1922149A (zh) *	2003-12-29	2007-02-28	塞普拉科公司	吡咯和吡唑daao抑制剂
RU2281755C2 (ru) *	2004-04-19	2006-08-20	Пятигорская государственная фармацевтическая академия	Композиция - лекарственная форма противоартрозного средства глюкозамина гидрохлорида для ректального применения
US20060002999A1 (en) *	2004-06-17	2006-01-05	Forest Laboratories, Inc.	Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
CA2614282A1 (fr)	2005-07-06	2007-01-11	Sepracor Inc.	Combinaisons d'eszopiclone et de trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-naphtalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphtalenamine, et methodes de traitement de la menopause et des troubles de l'humeur, de l'anxiete et troubles cognitifs
EP1976513B1 (fr)	2006-01-06	2016-08-24	Sunovion Pharmaceuticals Inc.	Cycloalkylamines inhibiteurs du recaptage des monoamines
KR101381768B1 (ko) *	2006-01-06	2014-04-07	선오비온 파마슈티컬스 인코포레이티드	테트랄론-기재 모노아민 재흡수 저해제
PT2816024T (pt)	2006-03-31	2017-10-20	Sunovion Pharmaceuticals Inc	Aminas quirais
US7579370B2 (en) *	2006-06-30	2009-08-25	Sepracor Inc.	Fused heterocycles
US7884124B2 (en) *	2006-06-30	2011-02-08	Sepracor Inc.	Fluoro-substituted inhibitors of D-amino acid oxidase
US20080082066A1 (en) *	2006-10-02	2008-04-03	Weyerhaeuser Co.	Crosslinked carboxyalkyl cellulose fibers having non-permanent and temporary crosslinks
EP1942104A1 (fr)	2006-12-20	2008-07-09	sanofi-aventis	Hétéroarylcyclopropanecarboxamide et leur utilisation pharmaceutique
JP2010516697A (ja) *	2007-01-18	2010-05-20	セプラコールインク．	Ｄ−アミノ酸オキシダーゼ阻害剤
US7902252B2 (en) *	2007-01-18	2011-03-08	Sepracor, Inc.	Inhibitors of D-amino acid oxidase
WO2008151156A1 (fr)	2007-05-31	2008-12-11	Sepracor Inc.	Cycloalkylamines substitués par un phényle en tant qu'inhibiteur du recaptage de monoamine
US20090247644A1 (en) *	2008-03-28	2009-10-01	Forest Laboratories Holdings Limited	Memantine formulations
US20100120740A1 (en) *	2008-08-07	2010-05-13	Sepracor Inc.	Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
US20110319463A1 (en) *	2009-03-10	2011-12-29	Saten Pharamaceuticals Co., Ltd.	Preventive or therapeutic agents for optic nerve disorders comprising 4,6-dichloro-1h-indole-2-carboxylic acid derivatives or salts thereof as active ingredients
US20110034434A1 (en) *	2009-08-07	2011-02-10	Sepracor Inc.	Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
US9737531B2 (en)	2012-07-12	2017-08-22	Glytech, Llc	Composition and method for treatment of depression and psychosis in humans
CA2946153C (fr)	2014-04-30	2022-06-14	Yufeng Jane Tseng	Utilisation de composes connus comme inhibiteurs de d-acide amine oxydase (daao)
CA3036250C (fr)	2016-09-14	2023-09-26	Yufeng Jane Tseng	Nouveaux derives de benzimidazole substitues utilises en tant qu'inhibiteurs de la d-amino-acide oxydase (daao)
CN110996948A (zh)	2017-06-12	2020-04-10	格莱泰施有限责任公司	用nmda拮抗剂和d2/5ht2a或选择性5ht2a拮抗剂治疗抑郁症
CN112707874A (zh) *	2020-12-29	2021-04-27	广东中科药物研究有限公司	一种抗病毒化合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3010971A (en) *	1960-08-04	1961-11-28	Smith Kline French Lab	Cyclopropylamine derivatives and processes for their preparation
DK500285A (da) *	1984-11-02	1986-05-03	Glaxo Group Ltd	Cephalosporinantibiotika
US4960786A (en) *	1989-04-24	1990-10-02	Merrell Dow Pharmaceuticals Inc.	Excitatory amino acid antagonists
PT93943A (pt) *	1989-05-05	1991-02-08	Searle & Co	Processo para a preparacao de composicoes contendo compostos indole-2-carboxilato para tratamento de perturbacoes do snc
EP0539503B1 (fr) *	1990-07-16	1996-04-03	Merrell Dow Pharmaceuticals Inc.	Antagonistes des acides amines excitateurs
US5284862A (en) *	1991-03-18	1994-02-08	Warner-Lambert Company	Derivatives of 2-carboxyindoles having pharmaceutical activity
US5145845A (en) *	1991-05-14	1992-09-08	Warner-Lambert Co.	Substituted 2-carboxylindoles having pharmaceutical activity

1992
- 1992-04-16 GB GB929208492A patent/GB9208492D0/en active Pending
1993
- 1993-04-14 ZA ZA932642A patent/ZA932642B/xx unknown
- 1993-04-15 FR FR9304452A patent/FR2690919B1/fr not_active Expired - Fee Related
- 1993-04-15 HU HU9402975A patent/HU217964B/hu not_active IP Right Cessation
- 1993-04-15 US US08/047,429 patent/US5374648A/en not_active Expired - Fee Related
- 1993-04-15 CA CA002094073A patent/CA2094073A1/fr not_active Abandoned
- 1993-04-15 GB GB9307808A patent/GB2266091B/en not_active Expired - Fee Related
- 1993-04-15 CN CN93105797A patent/CN1042331C/zh not_active Expired - Fee Related
- 1993-04-15 CZ CZ942543A patent/CZ285799B6/cs not_active IP Right Cessation
- 1993-04-15 IL IL105412A patent/IL105412A/en not_active IP Right Cessation
- 1993-04-15 AU AU36923/93A patent/AU666927B2/en not_active Ceased
- 1993-04-15 WO PCT/EP1993/000938 patent/WO1993021153A1/fr not_active Ceased
- 1993-04-15 JP JP5088844A patent/JPH0649027A/ja active Pending
- 1993-04-15 PL PL93305554A patent/PL176451B1/pl unknown
- 1993-04-15 CA CA002094076A patent/CA2094076A1/fr not_active Abandoned
- 1993-04-15 BE BE9300371A patent/BE1006343A5/fr active
- 1993-04-15 CA CA002094075A patent/CA2094075A1/fr not_active Abandoned
- 1993-04-15 NZ NZ247413A patent/NZ247413A/en unknown
- 1993-04-15 CH CH1133/93A patent/CH685630A5/fr not_active IP Right Cessation
- 1993-04-15 IS IS3994A patent/IS3994A/is unknown
- 1993-04-15 KR KR1019940703668A patent/KR100264114B1/ko not_active Expired - Fee Related
- 1993-04-15 MX MX9302195A patent/MX9302195A/es not_active IP Right Cessation
- 1993-04-15 LU LU88248A patent/LU88248A1/fr unknown
- 1993-04-15 AT AT0075293A patent/AT403917B/de not_active IP Right Cessation
- 1993-04-15 EP EP93201103A patent/EP0568136A1/fr not_active Withdrawn
- 1993-04-15 RU RU94045915A patent/RU2129544C1/ru active
- 1993-04-15 JP JP5517997A patent/JPH07505407A/ja active Pending
- 1993-04-15 RO RO94-01658A patent/RO113242B1/ro unknown
- 1993-04-15 US US08/046,947 patent/US5373018A/en not_active Expired - Fee Related
- 1993-04-15 SE SE9301241A patent/SE504336C2/sv not_active IP Right Cessation
- 1993-04-15 MY MYPI93000690A patent/MY112232A/en unknown
- 1993-04-15 GR GR930100154A patent/GR1001619B/el not_active IP Right Cessation
- 1993-04-15 DK DK043193A patent/DK169890B1/da active
- 1993-04-15 ES ES09300771A patent/ES2105924B1/es not_active Expired - Lifetime
- 1993-04-15 SK SK1241-94A patent/SK281941B6/sk unknown
- 1993-04-15 IT IT93RM000236A patent/IT1265325B1/it active IP Right Grant
- 1993-04-15 US US08/047,430 patent/US5374649A/en not_active Expired - Fee Related
- 1993-04-16 AP APAP/P/1993/000524A patent/AP480A/en active
- 1993-04-16 GE GEAP19932602A patent/GEP19991704B/en unknown
- 1993-05-06 TW TW082103531A patent/TW224457B/zh active
1994
- 1994-10-10 OA OA60570A patent/OA10103A/en unknown
- 1994-10-12 FI FI944800A patent/FI106198B/fi active
- 1994-10-14 BG BG99111A patent/BG62136B1/bg unknown
- 1994-10-14 NO NO943913A patent/NO301879B1/no not_active IP Right Cessation
- 1994-12-08 US US08/351,762 patent/US5510367A/en not_active Expired - Fee Related
1995
- 1995-06-29 HU HU95P/P00538P patent/HU211826A9/hu unknown
1997
- 1997-04-22 BR BR1100323-5A patent/BR1100323A/pt active IP Right Grant
- 1997-06-26 HK HK95797A patent/HK95797A/xx not_active IP Right Cessation
1998
- 1998-04-30 CY CY9802038A patent/CY2038B1/xx unknown

Also Published As

Publication number	Publication date
FR2690919A1 (fr)	1993-11-12
ES2105924A1 (es)	1997-10-16
ZA932642B (en)	1994-01-10
IL105412A (en)	1998-02-22
HK95797A (en)	1997-08-08
HUT70526A (en)	1995-10-30
US5374648A (en)	1994-12-20
GB2266091B (en)	1995-08-09
NO943913L (no)	1994-12-14
SK124194A3 (en)	1995-05-10
IL105412A0 (en)	1993-08-18
MX9302195A (es)	1994-03-31
JPH0649027A (ja)	1994-02-22
NO301879B1 (no)	1997-12-22
SE9301241D0 (sv)	1993-04-15
AP480A (en)	1996-03-22
GB9307808D0 (en)	1993-06-02
IT1265325B1 (it)	1996-10-31
IS3994A (is)	1993-10-17
OA10103A (en)	1996-12-18
AT403917B (de)	1998-06-25
EP0568136A1 (fr)	1993-11-03
ES2105924B1 (es)	1998-07-01
FR2690919B1 (fr)	1995-05-05
CA2094076A1 (fr)	1993-10-17
BE1006343A5 (fr)	1994-07-26
BG62136B1 (bg)	1999-03-31
CH685630A5 (fr)	1995-08-31
ITRM930236A1 (it)	1994-10-15
HU217964B (hu)	2000-05-28
CA2094075A1 (fr)	1993-10-17
ATA75293A (de)	1997-11-15
DK169890B1 (da)	1995-03-27
US5373018A (en)	1994-12-13
AP9300524A0 (en)	1993-04-30
TW224457B (fr)	1994-06-01
BG99111A (bg)	1995-05-31
GB9208492D0 (en)	1992-06-03
RU94045915A (ru)	1996-09-10
LU88248A1 (fr)	1994-03-01
CY2038B1 (en)	1998-04-30
FI944800A0 (fi)	1994-10-12
JPH07505407A (ja)	1995-06-15
WO1993021153A1 (fr)	1993-10-28
CA2094073A1 (fr)	1993-10-17
DK43193A (da)	1993-10-17
CZ254394A3 (en)	1995-07-12
GEP19991704B (en)	1999-08-05
FI106198B (fi)	2000-12-15
GB2266091A (en)	1993-10-20
DK43193D0 (da)	1993-04-15
BR1100323A (pt)	2000-06-27
SK281941B6 (sk)	2001-09-11
KR100264114B1 (ko)	2000-11-01
HU211826A9 (en)	1995-12-28
CN1085212A (zh)	1994-04-13
CN1042331C (zh)	1999-03-03
AU666927B2 (en)	1996-02-29
FI944800L (fi)	1994-10-12
NZ247413A (en)	1995-12-21
PL176451B1 (pl)	1999-05-31
HU9402975D0 (en)	1995-02-28
AU3692393A (en)	1993-10-21
MY112232A (en)	2001-05-31
RO113242B1 (ro)	1998-05-29
US5374649A (en)	1994-12-20
GR1001619B (el)	1994-07-29
NO943913D0 (no)	1994-10-14
US5510367A (en)	1996-04-23
SE9301241L (sv)	1993-10-17
ITRM930236A0 (it)	1993-04-15
RU2129544C1 (ru)	1999-04-27
CZ285799B6 (cs)	1999-11-17

Legal Events

Date

Code

Title

Description

2002-11-19

NUG

Patent has lapsed

Ref document number: 9301241-7

Format of ref document f/p: F

Publication	Publication Date	Title
DK169890B1 (da)	1995-03-27	3-Substitueret 2-carboxy-indolderivater, farmaceutisk præparat indeholdende forbindelserne, fremgangsmåde til fremstilling af forbindelserne samt anvendelse af forbindelserne til fremstilling af et lægemiddel
US5686461A (en)	1997-11-11	Indole derivatives
AP877A (en)	2000-09-27	Tetrahydroquinoline derivatives as EAA antagonists.
SK44996A3 (en)	1997-01-08	Indole derivatives, manufacturing process thereof and pharmaceutical composition containing them
US5977136A (en)	1999-11-02	Tetrahydroquinolines as NMDA antagonists
HU187340B (en)	1985-12-28	Process for the preparation of new 5-substituted-5,10-dihydro-11h-bibenzo-bracket-b,e-bracket closed-bracket-1,4-bracket closed-diazepin-11-ones
WO1995007887A1 (fr)	1995-03-23	Derives d'indole utilises comme antagonistes d'acides amines excitateurs
CA1335996C (fr)	1995-06-20	Carbonylimidazo(4,5)quinolines substituees en position 2